734
Views
14
CrossRef citations to date
0
Altmetric
Review

Current challenges and controversies in the management of chronic spontaneous urticaria

, , , , &
Pages 1073-1082 | Published online: 15 Jul 2015
 

Abstract

Chronic spontaneous urticaria (CSU) is characterized by the recurrence of itchy wheals for at least 6 weeks, affects up to 1% of the general population and may severely impair quality of life. H1-antihistamines are the cornerstones of treatment, but in about 10% of cases they fail to control the disease even at higher than licensed doses. In these patients, short courses of oral steroids may induce a remission in about 50% of cases. Omalizumab, a monoclonal anti-IgE, is effective in antihistamine-unresponsive patients although optimal treatment duration needs to be defined. Immunosuppressive treatment with cyclosporine is also effective in the majority of antihistamine-resistant chronic spontaneous urticaria (CSU) patients, but its use is limited by potential side effects. In refractory patients, other approaches include intravenous immunoglobulin, rituximab, dapsone and anticoagulants. The present review looks with particular interest at the prevalence of treatment failures with the main third-level treatments (corticosteroids, omalizumab and cyclosporine) and discusses them in light of the possible different pathogenic mechanisms underlying chronic spontaneous urticaria.

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Key issues
  • Chronic spontaneous urticaria is a frequent disorder that may heavily worsen the quality of life.

  • Chronic spontaneous urticaria may be severe and unresponsive to H1-antihistamine treatment.

  • In severely affected patients, several drugs have been used but only systemic steroids, cyclosporine and omalizumab are presently recommended by the guidelines.

  • Systemic steroids are extremely effective but cannot be used in the long term due to side effects.

  • Cyclosporine is effective and can be used for long-term treatments, but is associated with some side effects and many pharmacological interactions.

  • Omalizumab is effective and well tolerated but quite expensive.

  • Some patients fail to respond to one or more of these three drugs.

  • A better knowledge of the pathogenic mechanisms underlying the disease will lead to understand better the reasons for these failures and to a more patient-tailored therapy.

Notes

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 99.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 718.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.